Patient History

• Reggie was diagnosed at birth and was initiated on weekly rFVIII prophylaxis from 1 year of age after a right knee hemorrhage
• He developed an inhibitor at 2 years of age that was eradicated with immune tolerance induction (ITI)
  

  –	On-demand rFVIIa used for bleeding episodes prior to ITI procedure while waiting for the titer to drop to <10 BU
  –	rFVIIa was also used to provide perioperative hemostasis for placement of a subcutaneous port to facilitate regular rFVIII infusions for ITI

• 3x weekly rFVIII prophylaxis initiated at age 6 when he learned to self-infuse
• Reggie's disease was well managed throughout childhood and adolescence on his prophylaxis regimen

Mark T. Reding, MD Associate Professor of Medicine Director, Center for Bleeding and Clotting Disorders University of Minnesota Medical Center